
A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium
Keywords: Biomarker; Non–small cell; Src inhibitor; Systemic therapy